NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/16/2026 12:16
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization54.16 mln
Float16.43 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
39
/ 100
Underperforming
Debt / Equity
0.56
Moderate leverage
ROE
-50.49
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Boundless Bio is a San Diego-based clinical-stage company focused on developing new cancer treatments that target extrachromosomal DNA, a key driver of tumor growth in certain cancers. Its lead drug candidate, BBI-940, is currently being tested in Phase 1/2 clinical trials for patients with specific types of breast cancer. The company was founded in 2018 and was previously known as Pretzel Therapeutics before rebranding in July 2019.
